Enhanced targeting of FTY720 through CD37 and CD19 dual immunoliposomes may improve the clinical efficacy of FTY720 in B-Cell lymphocytic leukaemia [244]. Here, CD37 is linked to B-cell chronic lymphocytic leukemia.